Safety and Efficacy of 9 Days Vein-to-Vein Decentralized Manufactured Anti-CD19 CAR T-Cell Therapy for Relapsed/Refractory B-cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2024-09, Vol.24, p.S248-S248
Main Authors: Kumar Palani, Hamenth, Kumar Arunachalam, Arun, Yasar, Mohammad, Prakash Kulkarni, Uday, Selvarajan, Sushil, Korula, Anu, Abraham, Aby, George, Biju, Mathews, Vikram
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2152-2650
DOI:10.1016/S2152-2650(24)01029-2